VA-INTELSAT
22.11.2021 11:02:12 CET | Business Wire | Press release
Intelsat , operator of the world's largest integrated satellite and terrestrial network, announces the expansion of its global FlexMaritime service, now enabling connectivity for vessels traveling in Indian territorial waters and immediately enhancing the service coverage for all of Intelsat’s 8,000 existing FlexMaritime vessels. The landmark development also provides access for Indian-registered vessels to Intelsat’s award-winning global high-throughput maritime network. Intelsat's expansion is made possible by a new in-country gateway that is operationally ready to provide service via Intelsat’s HTS satellites under India-based partner Cloudcast 's In-Flight and Maritime Connectivity (IFMC) license.
FlexMaritime provides high-speed, resilient connectivity service with 99.95% proven network uptime. The expansion of FlexMaritime into India will open new business opportunities and accelerate digital transformation for thousands of Indian-flagged vessels and ships trading in Indian territorial waters. According to the Ministry of Shipping , around 95% of India's trading by volume and 70% by value is done through maritime transport.
"The completion of this regulatory milestone means customers of our FlexMaritime solutions partners will immediately benefit from the well-known power, performance and resilience of the FlexMaritime service in Indian waters," said Intelsat Senior Vice President of Mobility, Mark Rasmussen. "The network expansion also demonstrates Intelsat's commitment to mobility services providing yet another new dimension of global trade with access for Indian companies."
Intelsat has experienced continued growth in its FlexMaritime service. More than 8,000 vessels benefit from unrivaled network density and a global, multi-layered high-throughput satellite (HTS) fabric that enables partners to create unique service packages at enterprise-grade performance levels. With terminal sizes of 37cm, 45cm, 60cm and 1 meter, FlexMaritime meets the connectivity needs of every type of vessel with scale and global reach, even in high-traffic port locations.
The gateway will be located in Noida, India, serving as a critical link between Intelsat's terrestrial ground network and space assets and extending Intelsat's existing global network to a vital trading port.
Services are slated for availability at the beginning of 2022 through Intelsat's many solutions partners.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world's most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world's first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and "Imagine Here," with us, at Intelsat.com
.
About Cloudcast
Cloudcast is a 100% subsidiary of Planetcast Media Services Limited and is focused on growing the business in satellite communications and promoting excellence in Value Added Services, Business Practices, Technology and Operations. Cloudcast has commercial licenses for VSAT, ISP, and the new IFMC Gateway Services in India. Planetcast, the parent company, has over the years been instrumental in providing cutting-edge technology to enhance broadcast services. The Planetcast Group's ability to conceptualize, architect, and implement new and expanded capabilities allows clients to take their business to the next level. It is a key market player in providing technology-led managed services to the broadcasting industry in India.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005896/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom